Table 3 Site wise treatment outcome and parasite clearance time with artemether-lumefantrine
S. no. | Outcome of treatment (28Â days) | MP | CG | MH | OD | Total |
|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | ||
1 | Primary classification | |||||
 ACPR. | 103 (100) | 104 (96.3) | 82 (100) | 63(100) | 352 (98.9) | |
 ETF | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
 LCF | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
 LPF | 0 (0.0) | 4 (3.7) | 0 (0.0) | 0 (0.0) | 4 (1.1) | |
 Loss to follow-up | 0 (0.0) | 4 (3.4) | 0 (0.0) | 4 (5.6) | 8 (2.1) | |
 Withdrawal | 2 (1.9) | 5 (4.3) | 0 (0.0) | 5 (6.9) | 12 (3.2) | |
 Total | 105 (100) | 117 (100) | 82 (100) | 72 (100) | 376 (100) | |
2 | Parasite clearance time (hours) | |||||
 ≤ 24 | 86 (83.5) | 39 (36.1) | 79 (96.3) | 24(38.1) | 228 (64.0) | |
 > 24–48 | 17 (16.5) | 68(63.0) | 3 (3.7) | 37 (58.7) | 125 (35.1) | |
 > 48–72 | 0 (0.0) | 1 (0.9) | 0 (0.0) | 2 (3.2) | 3 (0.8) | |
 > 72 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |